大庆华科(000985) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 399,752,072.69, a 37.26% increase year-on-year[4] - Net profit attributable to shareholders rose by 85.82% to CNY 20,797,395.27 for the quarter[4] - The basic earnings per share increased by 86.05% to CNY 0.160[4] - Total revenue for the year-to-date reached CNY 1,093,382,320.70, a 53.19% increase compared to the same period last year[10] - The company reported a significant increase in operating income, driven by higher sales prices and volumes of chemical products[10] - The company’s profit margin improved, with total profit for the quarter increasing by 99.73% to CNY 24,079,412.86[10] - Operating revenue for the third quarter reached ¥1,295,385,775.68, an increase of 59.33% compared to the previous year[11] - Total profit amounted to ¥43,949,321.68, reflecting a growth of 102.19% year-on-year[11] Cash Flow and Assets - Cash flow from operating activities for the year-to-date was CNY 107,861,035.48, up 36.21%[4] - The company’s cash and cash equivalents increased by 52.37% to CNY 248,508,440.47 due to increased product sales revenue[10] - Cash received from sales of goods and services increased by ¥482,344,670.86 compared to the same period last year[11] - Cash paid for purchasing goods and services was ¥1,077,957,418.82, up 66.81% year-on-year, driven by increased raw material purchases[11] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,209[6] - The company distributed cash dividends amounting to ¥16,204,937.50 during the reporting period[11] Costs and Investments - The cost of goods sold was ¥976,219,620.30, which is a 59.09% increase year-on-year, primarily due to rising raw material prices and increased sales volume[11] - Fixed asset investment decreased by 49.50% to ¥11,328,710.12 compared to the previous period[11] Non-Operating Income - Non-operating income surged to ¥11,424,770.90, marking a 632.42% increase, mainly from the transfer of intangible assets[11] - The company confirmed a profit of ¥9,904,100 from the technology transfer of a new drug, completed in the reporting period[11] Other Information - Total assets increased by 7.48% to CNY 712,347,455.04 compared to the end of the previous year[4] - The company has not engaged in any securities or derivative investments during the reporting period[13]